13.66
10-January-25 12:39:45
15 minutes delayed
Stocks
-0.59
-4.14%
Today's range
13.42 - 14.20
ISIN
N/A
Source
NASDAQ
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
10 Jan 2025 08:00:00 By Nasdaq GlobeNewswire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
08 Jan 2025 08:00:01 By Nasdaq GlobeNewswire